NBC Securities Inc. Buys 3,351 Shares of Envista Holdings Co. (NYSE:NVST)

NBC Securities Inc. increased its stake in Envista Holdings Co. (NYSE:NVST) by 60.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,879 shares of the company’s stock after purchasing an additional 3,351 shares during the period. NBC Securities Inc.’s holdings in Envista were worth $189,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of NVST. Envestnet Asset Management Inc. increased its position in shares of Envista by 276.8% in the third quarter. Envestnet Asset Management Inc. now owns 175,141 shares of the company’s stock worth $4,883,000 after purchasing an additional 128,656 shares during the period. Algert Global LLC bought a new position in shares of Envista in the third quarter worth $748,000. Covestor Ltd increased its position in shares of Envista by 33.9% in the third quarter. Covestor Ltd now owns 2,462 shares of the company’s stock worth $69,000 after purchasing an additional 624 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Envista by 5.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 117,921 shares of the company’s stock worth $3,288,000 after purchasing an additional 5,610 shares during the period. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Envista in the third quarter worth $47,000.

Envista Stock Up 1.2 %

Shares of NVST opened at $17.41 on Friday. Envista Holdings Co. has a 1 year low of $16.74 and a 1 year high of $36.14. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.93 and a current ratio of 2.27. The business has a 50-day moving average of $18.80 and a 200-day moving average of $21.33.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). Envista had a positive return on equity of 5.84% and a negative net margin of 4.70%. The company had revenue of $623.60 million for the quarter, compared to the consensus estimate of $634.85 million. During the same quarter last year, the business earned $0.38 earnings per share. Envista’s revenue was down .6% compared to the same quarter last year. Equities research analysts anticipate that Envista Holdings Co. will post 1.23 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on NVST. The Goldman Sachs Group reduced their price objective on Envista from $20.00 to $17.50 and set a “sell” rating on the stock in a research note on Friday, May 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Monday, June 3rd. Morgan Stanley lowered Envista from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $33.00 to $21.00 in a research note on Friday, April 26th. Robert W. Baird reduced their price objective on Envista from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, May 2nd. Finally, JPMorgan Chase & Co. reduced their price objective on Envista from $29.00 to $23.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.86.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.